ADC Therapeutics (ADCT) Stock Statistics & Valuation Metrics

ADC Therapeutics has a market cap or net worth of $142.82M. The enterprise value is $81.87M.

ADC Therapeutics has 99,178,280 shares outstanding. The number of shares has decreased by -2.65% in one year.

ADC Therapeutics’s return on equity (ROE) is 0.78 and return on invested capital (ROIC) is -54.04%.

The current PE Ratio of ADC Therapeutics is -1.22. ADC Therapeutics’s PEG ratio is 0.03.

In the last 12 months, ADC Therapeutics had revenue of 69.28M and earned -157.85M in profits. Earnings per share was -1.62.

In the last 12 months, operating cash flow was -133.79M and capital expenditures -1.09M, giving a free cash flow of -134.89M billion.

ADC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

ADC Therapeutics upcoming earnings date is May 12, 2025, TBA Not Confirmed.

ADC Therapeutics as a current ratio of 3.82, with Debt / Equity ratio of -192.80%

In the past 12 months, ADC Therapeutics has paid -166.00K in taxes.

ADC Therapeutics EV to EBITDA ratio is -2.07, with an EV/FCF ratio of -2.17.

ADC Therapeutics has $274.27M in cash and marketable securities with $0.00 in debt, giving a net cash position of $57.24M billion.

Gross margin is 89.43%, with operating margin of -188.59%, and net profit margin of -227.84%.

The average price target for ADC Therapeutics is $7.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy